China Myasthenia Gravis Treatment Market Size & Outlook
China myasthenia gravis treatment market, 2018-2032 (US$M)
Related Markets
China myasthenia gravis treatment market highlights
- The China myasthenia gravis treatment market generated a revenue of USD 10.4 million in 2021 and is expected to reach USD 59.0 million by 2032.
- The China market is expected to grow at a CAGR of 17.1% from 2022 to 2032.
- In terms of segment, chronic immunomodulators was the largest revenue generating treatment type in 2021.
- Monoclonal Antibodies is the most lucrative treatment type segment registering the fastest growth during the forecast period.
Myasthenia gravis treatment market data book summary
| Market revenue in 2021 | USD 10.4 million |
| Market revenue in 2032 | USD 59.0 million |
| Growth rate | 17.1% (CAGR from 2021 to 2032) |
| Largest segment | Chronic immunomodulators |
| Fastest growing segment | Monoclonal Antibodies |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2032 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy |
| Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
Other key industry trends
- In terms of revenue, China accounted for 0.6% of the global myasthenia gravis treatment market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2032.
- In Asia Pacific, Japan myasthenia gravis treatment market is projected to lead the regional market in terms of revenue in 2032.
- Singapore is the fastest growing regional market in Asia Pacific and is projected to reach USD 1.8 million by 2032.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Myasthenia Gravis Treatment Market Scope
Myasthenia Gravis Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China myasthenia gravis treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Chronic immunomodulators was the largest segment with a revenue share of 30.77% in 2021. Horizon Databook has segmented the China myasthenia gravis treatment market based on cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy covering the revenue growth of each sub-segment from 2018 to 2032.
China is projected to exhibit significant growth in Asia Pacific region and is anticipated to be the most lucrative market for MG treatment drugs. This high growth can be attributed to presence of a large target population, increasing risk of MG with growing geriatric population, and continuous advancements in healthcare infrastructure.
Moreover, expanding biotechnology & pharmaceutical industry in the country and various strategic initiatives being undertaken by players to develop and gain approval for novel MG therapies in the region are expected to support market growth.
For instance, in January 2021, Hong Kong-based Harbour BioMed received Breakthrough Therapy designation from China Center for Drug Evaluation (CDE) for its new drug Batoclimab (HBM 9161). Batoclimab is a fully human anti-FcRn mAb intended for the treatment of adult patients affected with MG.
Reasons to subscribe to China myasthenia gravis treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China myasthenia gravis treatment market databook
-
Our clientele includes a mix of myasthenia gravis treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China myasthenia gravis treatment market , including forecasts for subscribers. This country databook contains high-level insights into China myasthenia gravis treatment market from 2018 to 2032, including revenue numbers, major trends, and company profiles.
Partial client list
China myasthenia gravis treatment market size, by treatment type, 2018-2032 (US$M)
China Myasthenia Gravis Treatment Market Outlook Share, 2021 & 2032 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
